MOUNTAIN VIEW, Calif. — Clad in T-shirts, the startup founders cycled through the stage, each whizzing through a two-minute pitch packed with wildly optimistic promises and generously large market estimates.

Some pitched the usual Silicon Valley fare, like drones and live-streamed fitness classes and laundry detergent subscriptions aimed at hip millennials. But more than ever before, many of them pitched ideas for the life sciences: Transistors for synthetic biology. An experimental cell therapy for patients with liver disease. And a diagnostic that aims to bypass needles altogether by collecting blood from women’s used menstrual pads — and in doing so collect reams of data that are invaluable to pharma companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Reading here about the bio startups that were selected by Ybio, and having been deprived of the chance of being part of it myself. More like, Y a combinator of incompetent people that don’t know squat.

  • FYI
    debuttante spells with a double TT, and the plural version is debuttanti. Doing your homework when adventuring in foreign territory is always a good approach.
    cheers

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy